BioVersys AG announces successful completion of Phase I clinical trials with BVL-GSK098
Basel, Switzerland. June 21, 2022 – BioVersys AG, a privately-held clinical stage, multi-asset Swiss pharmaceutical company focusing on research and development of small molecules for multidrug-resistant bacterial infections with applications in antimicrobial resistance (AMR) and targeted microbiome modulation, announced today the successful completion of Phase I clinical trials of BVL-GSK098.
Astrocyte Starts First-In-Human Phase 1 Study of Stroke and Traumatic Brain Injury Therapeutic
Groton, CT, June 15, 2022 – Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel cerebroprotective therapeutics for patients with brain injuries, announced that the Company’s first-in-human Phase 1 clinical study initiated today with the dosing of a first subject with AST-004. The promising investigational therapeutic, AST-004, is being advanced as a potential acute treatment for stroke and traumatic brain injury (TBI) victims, and as a chronic treatment for neurodegenerative diseases like Alzheimer’s. AST-004 has demonstrated a broad range of cerebroprotective efficacy when treating preclinical animal models, including preserving up to 45 percent more brain tissue in a non-human primate model of stroke, beyond that of reperfusion standard of care (study published in Stroke).
BioVersys raises CHF 24.2M
Basel, Switzerland. June 8, 2022 – BioVersys AG, a privately-held clinical stage, multi-asset Swiss pharmaceutical company focusing on research and development of therapies for life-threatening multidrug-resistant bacterial infections and targeted microbiome modulation, announced today that it has raised CHF 24.2 million in a first closing of its Series C round. This first closing was significantly oversubscribed by both existing and new investors from diverse geographies. BioVersys intends to complete the Series C investment round by the end of 2022.
Adiposs raises CHF 1.8M
GENEVA, SWITZERLAND – DECEMBER 24, 2021 – Adiposs SA, the developer of a unique diagnostic product for the non-invasive early detection of body wasting-cachexia, announced a CHF 1.8M first closing of its Pre-Series A round. The round was led by Privilège Ventures, a Swiss-based venture capital firm focused on seed and early-stage investments. Other investors include CR Ventures (CRV), Kick Foundation (Venture Kick), Fondation Genevoise pour l’Innovation Technologique (Fongit), a Singapore-based family office (Kingbridge), and a group of business angels. CR Ventures was the largest single investor.
Xeno Biosciences Raises $7.25m
Somerville, MA, Aug 8, 2021 – Xeno Biosciences Inc., a clinical stage drug discovery and development company advancing therapeutics for the treatment of obesity and metabolic diseases, announced today the completion of the Company’s Series A financing, which raised $7.25M in a private round. The investment round was led by Boston Harbor Angels. Clinical Research Ventures was the largest single investor.
Xeno is advancing its lead development candidate to address the unmet need for an effective and well-tolerated obesity treatment. Xeno has developed a substitute for gastric bypass in a daily oral pill that is clinic-ready with a large safety margin.
“We are honored and excited to have the support of an experienced and wide-ranging group of investors” said David Beno PhD, CEO. “This funding allows us to move XEN-101 to clinical proof-of-concept where we have the opportunity to show it as a safe and well-tolerated yet novel treatment for obesity and metabolic disease.”
“Xeno has the potential to fill the unmet need for a highly effective oral drug for obesity and related diseases with minimal side effects,” said Jeff Arnold, Director at Xeno since 2017. Arnold is a member of Boston Harbor Angels and led the Series A deal.